Understanding Lung Disease in Cystic Fibrosis Through Genetics and Epigenetics
Modulation of Lung Disease by Genetic/Epigenetic Profiling
['FUNDING_R01'] · SCRIPPS RESEARCH INSTITUTE, THE · NIH-11093467
This work aims to better understand how genetic and epigenetic differences in people with cystic fibrosis affect their lung disease, especially when current treatments like Trikafta don't fully help everyone.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SCRIPPS RESEARCH INSTITUTE, THE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11093467 on ClinicalTrials.gov |
What this research studies
Cystic fibrosis (CF) is a complex lung disorder where a protein called CFTR doesn't work correctly, leading to various health challenges. While a highly effective medicine called Trikafta has significantly improved outcomes for many, its impact can be incomplete and vary among individuals. This project seeks to uncover new ways to improve treatment by looking closely at how each person's unique genetic makeup and epigenetic factors (changes that affect how genes are expressed) influence their disease. By understanding these individual differences, we hope to find better strategies to manage CF and improve lung health.
Who could benefit from this research
Good fit: Patients with cystic fibrosis, particularly those who experience variable or incomplete responses to existing modulator therapies, could ultimately benefit from the insights gained from this research.
Not a fit: Patients without cystic fibrosis or related lung disorders would not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to new treatment approaches that are more effective for a wider range of people with cystic fibrosis, especially those who do not fully benefit from current therapies.
How similar studies have performed: Previous work by this team has shown promising findings related to the epigenetic environment's role in CF, providing a foundation for this continued investigation.
Where this research is happening
LA JOLLA, UNITED STATES
- SCRIPPS RESEARCH INSTITUTE, THE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BALCH, WILLIAM EDWARD — SCRIPPS RESEARCH INSTITUTE, THE
- Study coordinator: BALCH, WILLIAM EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bacterial Infections